#AI — The ambition behind the President’s recent Executive Order on AI, which we covered yesterday, is undeniably correct: we cannot allow a handful of progressive state legislatures in Sacramento and Denver to dictate the digital industrial policy of the entire United States. The issue is not just creating a patchwork. We can be sure that activists in blue states will use state legislation as a form of ideological lawfare designed to bake left-wing "equity" into the very foundations of American AI. However, the EO won't accomplish its stated goals.

The administration’s strategy relies heavily on the "Litigation Task Force" within the DOJ and the hope that the "Dormant Commerce Clause" will carry the day in court. But the judicial route is a slow-motion war of attrition. Furthermore, the attempt to "defund" non-compliant states by leveraging BEAD broadband grants is a classic Trumpian tactical maneuver, but one that invites immediate litigation. Blue-state Attorneys General are already mobilizing, and they view this as a fight for their sovereign right to regulate.

If we want to truly federalize AI and protect the American frontier from state-level "DEI" mandates, we cannot avoid legislation.

#PelosiTracker — Good news for good government. The House Administration Committee has passed the Stop Insider Trading Act, which effectively bars Members, their spouses, and dependent children from purchasing new publicly traded securities, while mandating a strict seven-to-fourteen-day public notice period for any sales of existing holdings. Just politics? Maybe. But then, why not pass it?

#Chyna #Biotech — The Coalition for a Prosperous America recently released a report titled "The China Dependence Big Pharma Doesn’t Want Washington to See." According to the report, since 2020, American drug giants have funneled over $53 billion into licensing deals with Chinese biopharma firms, effectively outsourcing the "intellectual engine" of US drug discovery to our primary geostrategic adversary. By 2024, nearly one-third of all new compounds in American drug pipelines originated in Chinese labs—a figure projected to hit 35% of all FDA approvals by 2040. This is not a mere supply chain issue; it is the wholesale transfer of the next generation of blockbuster therapies to an ecosystem deep in the pocket of the CCP’s military-civil fusion strategy.

The CPA correctly identifies that traditional "Fusionist" trade models have failed: while we focus on the retail end, the CCP has captured the high-value discovery phase. We are now in a position where 80% of U.S. biotech firms are embedded in a supply chain that Washington identifies as a national security threat. Without an aggressive pivot, we risk a future where American patients are permanently tethered to Beijing for life-saving innovation—innovation built with American capital but owned and weaponized by the CCP.

#VotingRights — Important: In a 7-2 vote, the Supreme Court rules that candidates for office have Article III standing to challenge the rules that govern the counting of votes in their elections, reviving Congressman Bost's challenge to the counting of late-arriving mail ballots in Illinois.

#Nukes #ToTheMoon — The Department of Energy has announced a partnership with NASA to develop a Lunar Surface Reactor by 2030.

#Childcare #Corruption — Tim Carney, scourge of special interests everywhere, has a great piece out pointing out that big government childcare programs are often a progressive racket.